Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma from Healthy Young People for ALS
NCT04454840Phase 1Completed
- Sponsor
- Peking University Third Hospital
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of young fresh frozen plasma in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale Score at 22 months. Started May 2016; status: completed.
02
Drugs
young fresh frozen plasma
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04454840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454840.